644 related articles for article (PubMed ID: 25975227)
1. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
2. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
3. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
5. Allosteric small-molecule kinase inhibitors.
Wu P; Clausen MH; Nielsen TE
Pharmacol Ther; 2015 Dec; 156():59-68. PubMed ID: 26478442
[TBL] [Abstract][Full Text] [Related]
6. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
7. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D
J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750
[TBL] [Abstract][Full Text] [Related]
9. Kinases--SMi conference: 9-10 April 2003, London, UK.
Harrison R
IDrugs; 2003 Jun; 6(6):560-2. PubMed ID: 12861985
[No Abstract] [Full Text] [Related]
10. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
12. Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
Rothweiler U; Eriksson J; Stensen W; Leeson F; Engh RA; Svendsen JS
Eur J Med Chem; 2015 Apr; 94():140-8. PubMed ID: 25768698
[TBL] [Abstract][Full Text] [Related]
13. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract][Full Text] [Related]
14. Kinases, homology models, and high throughput docking.
Diller DJ; Li R
J Med Chem; 2003 Oct; 46(22):4638-47. PubMed ID: 14561083
[TBL] [Abstract][Full Text] [Related]
15. Approval heralds new generation of kinase inhibitors?
Fletcher L
Nat Biotechnol; 2001 Jul; 19(7):599-600. PubMed ID: 11433254
[No Abstract] [Full Text] [Related]
16. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
Wu P; Nielsen TE; Clausen MH
Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of peanut serine/threonine/tyrosine protein kinase: molecular docking and inhibition kinetics with tyrosine kinase inhibitors.
Rudrabhatla P; Rajasekharan R
Biochemistry; 2004 Sep; 43(38):12123-32. PubMed ID: 15379551
[TBL] [Abstract][Full Text] [Related]
18. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets.
Vieth M; Higgs RE; Robertson DH; Shapiro M; Gragg EA; Hemmerle H
Biochim Biophys Acta; 2004 Mar; 1697(1-2):243-57. PubMed ID: 15023365
[TBL] [Abstract][Full Text] [Related]
19. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
20. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]